ARID1A and ovarian carcinoma: In mice with ARID1A‐deficient ovarian cancer, the therapeutic effect of PD‐L1 inhibitors was greatly enhanced, suggesting ICI treatment could be beneficial for ARID1A‐impaired patients.11